NeoplasiaCancer BiologyPeer-reviewed journal article
THOC1 complexes with SIN3A to regulate R-loops and promote glioblastoma progression
Shreya Budhiraja, Umme H FaisaliD, Shivani BaisiwalaiD, Rafał ChojakiD, Lara KoutahiD, Noah B. DrewesiD, Sia Cho, Hasaan A Kazi, Rebecca CheniD, Ella N. PerraultiD, Li Chen, Cheol H. Park, Maeve C. O’Shea, Khizar Rehan NandoliyaiD, Joseph T. DuffyiD, Peiyu Lin, Adam M. SonabendiD, Crismita DmelloiD, A. Karim AhmediD
Abstract
ABSTRACTGlioblastoma (GBM), the most common and aggressive malignant brain tumor in adults, has a median survival of 21 months. To identify drivers of GBM proliferation, we conducted a CRISPR-knockout screen, which revealed THO Complex 1 (THOC1) as a key driver. Knocking down THOC1 significantly reduced GBM cell viability across patient-derived xenograft (PDX) lines, enhancing survival (p<0.01) in primary PDX models. Conversely, overexpressing THOC1 in non-cancerous cells bolstered viability, decreasing survival and causing tumor engraftment in vivo (p<0.01). Further investigation revealed THOC1s robust interaction with SIN3A, a histone deacetylase complex. Histone deacetylation has been previously shown to prevent the buildup of R-loops, structures that form normally during transcription but can be lethal in excess. We found that THOC1-knockdown leads to elevated R-loop levels and reduced histone deacetylation levels. Next, to understand the networks specifically regulated by THOC1-mediated R-loop prevention, we conducted unbiased RNA-sequencing on control and THOC1-knockdown GBM cells. We found that THOC1s role in R-loop prevention primarily affects telomeres, critical regions for cell replication. We further show that THOC1-knockdown results in significantly increased telomeric R-loop levels and shortened telomeres. Ultimately, this study suggests that targeting THOC1 shows promise as a therapeutic strategy to disrupt the delicate R-loop landscape and undermine GBMs replicative potential.
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- approach: genetic perturbation / CRISPR
- Citations
- 1
- FWCI
- 0.00
- Field percentile
- 1th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage
A. M. Amen, C. Fellmann, … J. F. Costello·Proceedings of the National Academy of SciencesPeer-reviewed·Mar 23, 2021
- SUV39H1 Preserves Cancer Stem Cell Chromatin State and Properties in Glioblastoma
Chunying Li, Qiqi Xie, … Jia Shen·JCI InsightPeer-reviewed·Mar 9, 2025
- Acquisition and reversal of glioblastoma chemoresistance are mediated by the Rho GTPase pathway
Yuli Thamires Magalhães, Viktor Kalbermatter Boell, Fábio Luís Forti·Molecular Cancer TherapeuticsPeer-reviewed·Oct 28, 2025
- BRAT1 - a new therapeutic target for glioblastoma
Alicia Haydo, Jennifer Schmidt, … Benedikt Linder·Cellular and Molecular Life SciencesPeer-reviewed·Jan 20, 2025
- Tyrosine hydroxylase–mediated neuroimmune crosstalk regulates antitumor immunity in glioblastoma during oncolytic herpes virotherapy
Konstantina Kyritsi, Haocheng Ding, … Bangxing Hong·bioRxiv·Jun 23, 2026
- LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population During Temozolomide Therapy in Glioblastoma
A. U. Ahmed·bioRxiv·Sep 10, 2020